Featured Publications
Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
Adamkiewicz T, Yee M, Thomas S, Tunali A, Lai K, Omole F, Lane P, Yildirim I. Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines. Blood Advances 2023, 7: 6751-6761. PMID: 37698500, PMCID: PMC10660014, DOI: 10.1182/bloodadvances.2022009643.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSickle cell diseaseCell diseasePCV13-serotype invasive pneumococcal diseaseSerotype invasive pneumococcal diseaseNon-PCV13 serotypesPneumococcal polysaccharide vaccinePneumococcal conjugate vaccineIncidence rate ratiosYears of vaccinationReference populationLife-threatening risksIPD episodesIPD serotypesPneumococcal diseasePneumococcal infectionPolysaccharide vaccineConjugate vaccineHemoglobin SSVaccine licensureEffective vaccinePenicillin resistanceDisease controlVaccineAfrican American children
2021
Population-Based Surveillance of Pneumococcal Infections in Children with Sickle Cell Disease before and after Prevnar 7® and Prevnar 13® Licensure: Implications for Expanded Vaccination
Adamkiewicz T, Thomas S, Tunali A, Lai K, Yee M, Yildirim I, Lane P, Omole F, Farley M. Population-Based Surveillance of Pneumococcal Infections in Children with Sickle Cell Disease before and after Prevnar 7® and Prevnar 13® Licensure: Implications for Expanded Vaccination. Blood 2021, 138: 763. DOI: 10.1182/blood-2021-154474.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseSickle cell diseaseIPD ratesPCV periodPCV7 licensureMean ageRelative riskCell diseaseGeneral populationNew vaccinesNon-PCV13 serotypesPneumococcal polysaccharide vaccineRegistry of patientsPopulation-based surveillanceProphylactic antibiotic useEmory University Institutional Review BoardAntibiotic susceptibility testingInstitutional review boardUniversity Institutional Review BoardAge of infectionIPD diagnosisPCV eraPCV13 periodPCV13 serotypesPCV7 period